Skip to main content

Table 2 Laboratory characteristics

From: Prognostic impact of ICG-PDR in patients with hypoxic hepatitis

 

Patients with liver disease

HH

ALF

Cirrhosis

Control

Parameter

 n

97

52

10

35

22

 ICG-PDR, %/minb, c, e, f

5.7 (3.8–7.9)

7 (4.7–8.9)

5.7 (4.8–8.0)

4.1 (3.4–5.9)

20.7 (14.1–25.4)

 Bilirubin, mg/dla, b, c, e, f

3.7 (1.7–9.7)

2.2 (0.8–3.8)

23.8 (9.1–29.2)

7.7 (3.3–16.6)

0.8 (0.6–1.3)

 INRa, c, d, e, f

1.8 (1.5–2.3)

1.7 (1.4–2.3)

3.3 (2.1–5.2)

1.7 (1.4–2.2)

1.2 (1.1–1.3)

 AST, U/lb, c, d, e

1096 (133–3798)

2667 (1267–5015)

1815 (216–5289)

84 (55–202)

67 (38–418)

 ALT, U/lb, c, d, e

743 (76–2119)

1430 (871–2417)

2224 (202–6173)

43 (24–93)

54 (21–176)

 Lactate, mmol/lb

3.5 (2–6.2)

4 (2.3–9.3)

4 (2.3–5.3)

2.5 (1.8–4)

3 (1.8–3.6)

 Creatinine, mg/dla, c

1.5 (1–2.4)

1.7 (1.3–2.3)

0.9 (0.7–1.5)

1.2 (0.8–3.1)

1.1 (0.8–2)

  1. Data are shown as median and IQR
  2. AST aspartate aminotransferase level, ALT alanine aminotransferase level, INR international normalized ratio
  3. a p < 0.05 HH vs. ALF
  4. b p < 0.05 HH vs. cirrhosis
  5. c p < 0.05 HH vs. control
  6. d p < 0.05 ALF vs. cirrhosis
  7. e p < 0.05 ALF vs. control
  8. f p < 0.05 cirrhosis vs. control